| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stem Cell Transplantation | 4 | 2020 | 1360 | 0.970 |
Why?
|
| Antifungal Agents | 7 | 2020 | 834 | 0.940 |
Why?
|
| Bacteremia | 6 | 2021 | 689 | 0.860 |
Why?
|
| Voriconazole | 4 | 2020 | 108 | 0.840 |
Why?
|
| Salmonella Infections | 1 | 2021 | 40 | 0.810 |
Why?
|
| Periostitis | 1 | 2020 | 4 | 0.760 |
Why?
|
| Respiratory Tract Infections | 4 | 2018 | 437 | 0.740 |
Why?
|
| Immunocompromised Host | 5 | 2018 | 698 | 0.730 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2018 | 12 | 0.660 |
Why?
|
| HIV Infections | 4 | 2016 | 2134 | 0.660 |
Why?
|
| Ehrlichiosis | 1 | 2018 | 20 | 0.650 |
Why?
|
| Acyclovir | 1 | 2018 | 78 | 0.630 |
Why?
|
| Herpes Simplex | 2 | 2018 | 95 | 0.630 |
Why?
|
| Cough | 2 | 2018 | 116 | 0.620 |
Why?
|
| Consultants | 1 | 2017 | 14 | 0.620 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2021 | 6550 | 0.600 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2018 | 362 | 0.580 |
Why?
|
| Transplantation, Homologous | 5 | 2018 | 2843 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 9 | 2021 | 2992 | 0.540 |
Why?
|
| Neoplasms | 14 | 2023 | 15193 | 0.540 |
Why?
|
| Hematologic Neoplasms | 8 | 2019 | 1870 | 0.530 |
Why?
|
| Antiviral Agents | 4 | 2021 | 1230 | 0.510 |
Why?
|
| Herbaspirillum | 1 | 2014 | 6 | 0.510 |
Why?
|
| Communicable Diseases | 1 | 2017 | 193 | 0.510 |
Why?
|
| Blood Transfusion | 1 | 2018 | 583 | 0.500 |
Why?
|
| Graft Rejection | 1 | 2018 | 834 | 0.460 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 158 | 0.450 |
Why?
|
| Cross Infection | 3 | 2017 | 544 | 0.450 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 148 | 0.440 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2014 | 317 | 0.430 |
Why?
|
| Drug Interactions | 1 | 2014 | 553 | 0.430 |
Why?
|
| Anti-HIV Agents | 2 | 2014 | 350 | 0.420 |
Why?
|
| Immune Reconstitution | 2 | 2021 | 22 | 0.400 |
Why?
|
| Lung Diseases, Fungal | 1 | 2011 | 124 | 0.370 |
Why?
|
| Staphylococcus epidermidis | 1 | 2010 | 61 | 0.370 |
Why?
|
| Toxoplasmosis | 1 | 2010 | 28 | 0.370 |
Why?
|
| Oxazolidinones | 1 | 2010 | 60 | 0.360 |
Why?
|
| Acetamides | 1 | 2010 | 113 | 0.350 |
Why?
|
| Mycoses | 4 | 2016 | 386 | 0.340 |
Why?
|
| Drug Utilization | 1 | 2010 | 179 | 0.340 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2018 | 6915 | 0.320 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 672 | 0.320 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2010 | 418 | 0.320 |
Why?
|
| Leukemia | 5 | 2019 | 1635 | 0.310 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 415 | 0.310 |
Why?
|
| Drug Resistance, Viral | 2 | 2018 | 71 | 0.290 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2018 | 46 | 0.290 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 544 | 0.290 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 715 | 0.290 |
Why?
|
| Triazoles | 4 | 2014 | 617 | 0.290 |
Why?
|
| Plasma | 1 | 2007 | 158 | 0.280 |
Why?
|
| Catheter-Related Infections | 3 | 2016 | 270 | 0.280 |
Why?
|
| Retrospective Studies | 22 | 2023 | 37905 | 0.280 |
Why?
|
| Middle Aged | 33 | 2021 | 86204 | 0.270 |
Why?
|
| Aged | 28 | 2021 | 70117 | 0.270 |
Why?
|
| Humans | 56 | 2023 | 261506 | 0.260 |
Why?
|
| Pneumonia | 1 | 2011 | 751 | 0.260 |
Why?
|
| Neutropenia | 2 | 2021 | 968 | 0.240 |
Why?
|
| Central Venous Catheters | 2 | 2016 | 98 | 0.240 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2018 | 181 | 0.230 |
Why?
|
| Male | 40 | 2021 | 123000 | 0.230 |
Why?
|
| DNA, Ribosomal | 2 | 2014 | 103 | 0.220 |
Why?
|
| Female | 34 | 2021 | 141928 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Adult | 26 | 2023 | 77950 | 0.210 |
Why?
|
| Graft vs Host Disease | 4 | 2018 | 2638 | 0.210 |
Why?
|
| Salmonella | 1 | 2021 | 35 | 0.210 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2015 | 157 | 0.210 |
Why?
|
| Minocycline | 2 | 2016 | 182 | 0.200 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 14 | 0.200 |
Why?
|
| Influenza, Human | 2 | 2021 | 925 | 0.200 |
Why?
|
| Convalescence | 1 | 2021 | 25 | 0.200 |
Why?
|
| Febrile Neutropenia | 1 | 2021 | 65 | 0.200 |
Why?
|
| Common Cold | 1 | 2021 | 46 | 0.200 |
Why?
|
| Cluster Analysis | 3 | 2014 | 1053 | 0.200 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.200 |
Why?
|
| Betacoronavirus | 3 | 2021 | 527 | 0.200 |
Why?
|
| Mucormycosis | 2 | 2014 | 108 | 0.200 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 51 | 0.190 |
Why?
|
| Lymphopenia | 1 | 2023 | 199 | 0.190 |
Why?
|
| DNA, Bacterial | 2 | 2014 | 558 | 0.190 |
Why?
|
| Cystitis | 1 | 2021 | 107 | 0.180 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 222 | 0.170 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 5 | 0.170 |
Why?
|
| Bordetella Infections | 1 | 2018 | 4 | 0.170 |
Why?
|
| HIV Protease Inhibitors | 2 | 2014 | 72 | 0.160 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2014 | 61 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 1664 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 4 | 2014 | 2483 | 0.150 |
Why?
|
| Treatment Outcome | 15 | 2019 | 32848 | 0.150 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.150 |
Why?
|
| BK Virus | 1 | 2018 | 123 | 0.150 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2014 | 128 | 0.150 |
Why?
|
| Scedosporium | 1 | 2016 | 23 | 0.140 |
Why?
|
| Tacrolimus | 1 | 2018 | 335 | 0.140 |
Why?
|
| Coinfection | 1 | 2018 | 189 | 0.140 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 86 | 0.140 |
Why?
|
| Saccharomycetales | 1 | 2016 | 44 | 0.140 |
Why?
|
| Edetic Acid | 1 | 2016 | 73 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2013 | 3518 | 0.140 |
Why?
|
| Organophosphonates | 1 | 2016 | 64 | 0.140 |
Why?
|
| Adolescent | 11 | 2021 | 31252 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1016 | 0.130 |
Why?
|
| Genotype | 3 | 2014 | 4109 | 0.130 |
Why?
|
| Cytosine | 1 | 2016 | 141 | 0.130 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 175 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 406 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2019 | 426 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2015 | 74 | 0.130 |
Why?
|
| Empyema, Pleural | 1 | 1995 | 48 | 0.130 |
Why?
|
| Betaproteobacteria | 1 | 2014 | 6 | 0.130 |
Why?
|
| Herpesviridae Infections | 1 | 2016 | 175 | 0.130 |
Why?
|
| Burkholderia cepacia | 1 | 2014 | 7 | 0.130 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 152 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 884 | 0.130 |
Why?
|
| Aminoglycosides | 1 | 2015 | 220 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 1995 | 63 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 14289 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 2 | 2016 | 462 | 0.120 |
Why?
|
| Molecular Typing | 1 | 2014 | 55 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 285 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1320 | 0.120 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2014 | 20 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 163 | 0.120 |
Why?
|
| Vancomycin | 2 | 2015 | 273 | 0.120 |
Why?
|
| Ethanol | 1 | 2016 | 264 | 0.120 |
Why?
|
| Blood | 1 | 2014 | 156 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 3869 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 446 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2015 | 238 | 0.110 |
Why?
|
| Bacterial Typing Techniques | 2 | 2010 | 139 | 0.110 |
Why?
|
| Vancomycin Resistance | 1 | 2013 | 54 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2014 | 205 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 2016 | 354 | 0.110 |
Why?
|
| Tuberculosis | 1 | 2019 | 548 | 0.110 |
Why?
|
| Aspergillus | 1 | 2014 | 149 | 0.110 |
Why?
|
| Enterobacteriaceae | 1 | 2013 | 46 | 0.110 |
Why?
|
| Phaeohyphomycosis | 1 | 2012 | 12 | 0.110 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 2238 | 0.110 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2013 | 69 | 0.110 |
Why?
|
| Ascomycota | 1 | 2012 | 31 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2014 | 490 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 1375 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 899 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 264 | 0.100 |
Why?
|
| Opportunistic Infections | 2 | 2010 | 223 | 0.100 |
Why?
|
| Palate, Hard | 1 | 2010 | 12 | 0.100 |
Why?
|
| beta-Lactamases | 1 | 2013 | 179 | 0.100 |
Why?
|
| Coagulase | 1 | 2010 | 29 | 0.100 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2010 | 26 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 11538 | 0.090 |
Why?
|
| Linezolid | 1 | 2010 | 64 | 0.090 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 669 | 0.090 |
Why?
|
| Lung | 2 | 2020 | 3151 | 0.090 |
Why?
|
| DNA, Protozoan | 1 | 2010 | 35 | 0.090 |
Why?
|
| Pyomyositis | 1 | 2010 | 9 | 0.090 |
Why?
|
| Oncology Service, Hospital | 1 | 2010 | 48 | 0.090 |
Why?
|
| Daptomycin | 1 | 2010 | 39 | 0.090 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2014 | 427 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 2390 | 0.090 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 324 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 1581 | 0.090 |
Why?
|
| Parainfluenza Virus 2, Human | 1 | 2008 | 4 | 0.090 |
Why?
|
| Epiglottitis | 1 | 2008 | 16 | 0.080 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 308 | 0.080 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2010 | 87 | 0.080 |
Why?
|
| Croup | 1 | 2008 | 15 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 2138 | 0.080 |
Why?
|
| Incidence | 3 | 2019 | 5673 | 0.080 |
Why?
|
| Transplant Recipients | 2 | 2021 | 324 | 0.080 |
Why?
|
| Bacterial Infections | 2 | 2009 | 479 | 0.080 |
Why?
|
| Dirofilariasis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Dirofilaria immitis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2014 | 691 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 87 | 0.080 |
Why?
|
| Child, Preschool | 5 | 2017 | 16273 | 0.080 |
Why?
|
| Escherichia coli Infections | 1 | 2010 | 241 | 0.080 |
Why?
|
| Texas | 2 | 2019 | 6311 | 0.080 |
Why?
|
| Risk Factors | 5 | 2023 | 17523 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 3203 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 29902 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2010 | 1234 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 7551 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2015 | 2967 | 0.060 |
Why?
|
| Lymphoma | 2 | 2010 | 1467 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5319 | 0.060 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2023 | 53 | 0.060 |
Why?
|
| Animals | 3 | 2018 | 59536 | 0.060 |
Why?
|
| Comorbidity | 1 | 2010 | 2352 | 0.060 |
Why?
|
| Nasopharynx | 1 | 2023 | 119 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10035 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2009 | 1039 | 0.060 |
Why?
|
| Echinocandins | 2 | 2014 | 132 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 10331 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 109 | 0.050 |
Why?
|
| Amphotericin B | 2 | 2015 | 289 | 0.050 |
Why?
|
| Dibenzothiepins | 1 | 2021 | 6 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2021 | 33 | 0.050 |
Why?
|
| Lactates | 1 | 2021 | 112 | 0.050 |
Why?
|
| Stavudine | 1 | 2000 | 2 | 0.050 |
Why?
|
| Indinavir | 1 | 2000 | 8 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 1559 | 0.050 |
Why?
|
| Triazines | 1 | 2021 | 117 | 0.050 |
Why?
|
| Lamivudine | 1 | 2000 | 28 | 0.050 |
Why?
|
| Zidovudine | 1 | 2000 | 40 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 266 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 172 | 0.050 |
Why?
|
| Morpholines | 1 | 2021 | 289 | 0.050 |
Why?
|
| Haplotypes | 2 | 2012 | 856 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2016 | 2803 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 348 | 0.040 |
Why?
|
| JC Virus | 1 | 2018 | 43 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2018 | 191 | 0.040 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2018 | 33 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 754 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 577 | 0.040 |
Why?
|
| HIV Wasting Syndrome | 1 | 1997 | 5 | 0.040 |
Why?
|
| Biological Products | 1 | 2021 | 274 | 0.040 |
Why?
|
| United States | 2 | 2017 | 15433 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4849 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 12873 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 1904 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3251 | 0.040 |
Why?
|
| Metapneumovirus | 1 | 2017 | 58 | 0.040 |
Why?
|
| Viral Load | 1 | 2018 | 493 | 0.040 |
Why?
|
| Gram-Positive Cocci | 1 | 2015 | 10 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 672 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 4744 | 0.030 |
Why?
|
| HIV-1 | 1 | 2000 | 653 | 0.030 |
Why?
|
| Itraconazole | 1 | 2015 | 77 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 15862 | 0.030 |
Why?
|
| Prednisone | 1 | 1997 | 984 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 343 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 73 | 0.030 |
Why?
|
| Biofilms | 1 | 2016 | 199 | 0.030 |
Why?
|
| Hyphae | 1 | 2014 | 44 | 0.030 |
Why?
|
| Palivizumab | 1 | 2014 | 64 | 0.030 |
Why?
|
| Hypoxia | 1 | 2017 | 443 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 660 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 752 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 650 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 285 | 0.030 |
Why?
|
| Ribavirin | 1 | 2014 | 178 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2016 | 482 | 0.030 |
Why?
|
| Time Factors | 1 | 2007 | 12926 | 0.030 |
Why?
|
| Weight Loss | 1 | 1997 | 627 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 298 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 676 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 4971 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4892 | 0.030 |
Why?
|
| Transplantation | 1 | 2012 | 56 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2015 | 994 | 0.030 |
Why?
|
| Child | 4 | 2017 | 29154 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2012 | 127 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 329 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 2316 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 403 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.030 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 328 | 0.020 |
Why?
|
| Haploidy | 1 | 2010 | 40 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2014 | 677 | 0.020 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2010 | 33 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7702 | 0.020 |
Why?
|
| Infant | 2 | 2017 | 13310 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2010 | 167 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2012 | 299 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 1914 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2009 | 6207 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4298 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 573 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 486 | 0.020 |
Why?
|
| Nasal Lavage Fluid | 1 | 2008 | 19 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 126 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2010 | 246 | 0.020 |
Why?
|
| Hoarseness | 1 | 2008 | 25 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 6869 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2008 | 75 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2000 | 297 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 829 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2010 | 213 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 3341 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 130 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 739 | 0.020 |
Why?
|
| Saliva | 1 | 2008 | 231 | 0.020 |
Why?
|
| Vomiting | 1 | 2009 | 354 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2015 | 2358 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 3569 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 4758 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 525 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2010 | 359 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 755 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2359 | 0.020 |
Why?
|
| Dogs | 1 | 2008 | 1155 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 3719 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 2961 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 2422 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 6089 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4113 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2010 | 1203 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 1819 | 0.010 |
Why?
|
| Critical Care | 1 | 2008 | 770 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 21713 | 0.010 |
Why?
|
| Fatigue | 1 | 2008 | 1239 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 14889 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2012 | 9180 | 0.010 |
Why?
|
| Thymidine | 1 | 2000 | 155 | 0.010 |
Why?
|
| Neopterin | 1 | 1997 | 13 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2000 | 671 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 9244 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 4938 | 0.010 |
Why?
|